Talphera (NASDAQ:TLPH) Rating Increased to Hold at Zacks Research

Talphera (NASDAQ:TLPH) was upgraded by stock analysts at Zacks Research to a “hold” rating in a research note issued on Monday,Zacks.com reports.

Other research analysts also recently issued research reports about the company. HC Wainwright started coverage on Talphera in a research note on Friday, June 5th. They issued a “buy” rating and a $3.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a research note on Monday, April 20th. Finally, Westpark Capital started coverage on Talphera in a research note on Thursday, April 30th. They issued a “buy” rating and a $3.00 price target on the stock. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Talphera currently has a consensus rating of “Hold” and an average price target of $3.00.

Talphera Stock Down 3.7%

TLPH stock opened at $0.82 on Monday. The business’s fifty day moving average is $0.81 and its 200-day moving average is $0.94. The company has a market cap of $42.33 million, a P/E ratio of -2.63 and a beta of 0.76. Talphera has a twelve month low of $0.38 and a twelve month high of $1.57.

Talphera (NASDAQ:TLPH) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. Research analysts anticipate that Talphera will post -0.26 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Talphera news, CEO Vincent J. Angotti acquired 213,310 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The shares were acquired at an average price of $0.59 per share, with a total value of $125,852.90. Following the purchase, the chief executive officer owned 800,705 shares of the company’s stock, valued at $472,415.95. This represents a 36.31% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 3.50% of the company’s stock.

Institutional Trading of Talphera

Several hedge funds have recently added to or reduced their stakes in TLPH. Rosalind Advisors Inc. raised its stake in Talphera by 118.9% during the 3rd quarter. Rosalind Advisors Inc. now owns 4,385,757 shares of the company’s stock worth $3,917,000 after buying an additional 2,381,818 shares during the period. Nantahala Capital Management LLC raised its stake in Talphera by 75.3% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock worth $3,120,000 after buying an additional 1,500,000 shares during the period. Empery Asset Management LP acquired a new stake in Talphera during the 4th quarter worth $1,520,000. Cantor Fitzgerald L. P. acquired a new stake in Talphera during the 4th quarter worth $658,000. Finally, Renaissance Technologies LLC raised its stake in Talphera by 412.6% during the 4th quarter. Renaissance Technologies LLC now owns 257,380 shares of the company’s stock worth $293,000 after buying an additional 207,166 shares during the period. Institutional investors and hedge funds own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.